ブログ について MX Series Kits Advance Antibody Discovery Via Variable Region Amplification

Accurate determination of monoclonal antibody variable-region sequences is a critical step in antibody discovery and development, feeding directly into downstream functional validation and production. Designed for hybridoma and recombinant expression cell lines, the MX series antibody sequencing kit applies adapter-mediated cDNA synthesis to prepare mouse and human IgG antibody sequences for efficient amplification and sequencing.

Three-stage workflow from RNA to sequence-ready product

The kit amplifies antibody variable regions directly from total RNA. Its standard protocol proceeds through three core stages, each intended to sharpen specificity and preserve product purity.

• Reverse transcription. Specific primers bind conserved constant-region sequences, converting RNA into cDNA. The adapter sequence introduced at this step provides a uniform primer-binding site for the standardized amplification that follows.
• PCR amplification. A nested PCR design pairs adapter-complementary primers with reverse primers targeting a specific antibody chain type, substantially improving the specificity and yield of the target fragment.
• Sequencing preparation. The final product ranges from roughly 600 to 850 bp and, once purified, can be used directly for Sanger sequencing to resolve the DNA sequence of the antibody variable region.

The combination of adapter tagging and nested amplification is what allows the protocol to work from total RNA rather than requiring purified messenger RNA, according to the technical description of the method.

Expanded human IgG and light-chain coverage

The MX kit has been optimized relative to earlier versions, with the most substantial gains in coverage of human IgG antibodies across subclasses IgG1 through IgG4. Newly integrated human-specific constant-region primers extend the kit to full light-chain coverage, including both kappa and lambda chains.

Product lengths by chain type

Limitations and boundary conditions

The method performs robustly in monoclonal antibody sequencing, but several constraints define where it can be applied reliably.

• Isotype restriction. The kit is currently designed primarily for antibodies of the IgG isotype.
• Structural restriction. For antibodies whose constant regions have been engineered, primer-binding sites may be altered, and validation data for the kit remain insufficient.
• Sample quality. Samples with low RNA integrity can lead to amplification failure or truncated sequences.
• Sample type. The protocol suits monoclonal sources such as hybridomas, single B cells or recombinant cell lines. It cannot be used directly for repertoire analysis of polyclonal samples unless single-cell isolation is performed beforehand.

Because RNA integrity directly affects cDNA synthesis efficiency and fragment length, degraded input material may prevent recovery of a complete variable-region product. Assessing RNA quality before amplification is therefore a practical prerequisite for interpretable results.